Newsroom
All News
- All News
- In the News
- Press Releases
- Publications
- Events
At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time
From Leo O'Connor of LabPulse.com At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour. The SeptiCyte Rapid test is different from almost all other sepsis tests on the market by...
A multi-site study confirms the use of undiluted EDTA blood for the SeptiCyte RAPID sepsis assay
Data Validating EDTA Blood as Sample Type for SeptiCyte® RAPID Presented at the Association for Molecular Pathology 2022 Annual Meeting SEATTLE and BRISBANE, Australia, Nov. 3, 2022 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the presentation of an abstract at the Association for...
ContagionLive interview: A Rapid Sepsis Diagnostic Test for Better Patient Outcomes
Nina Cosdon of ContagionLive interviewed the chief medical officer of Immunexpress Inc., Roy Davis, MD, PhD, MHA, in a post titled A Rapid Sepsis Diagnostic Test for Better Patient Outcomes. Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in...
CEO Rolland Carlson: When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems
Immunexpress CEO Rolland Carlson was recently featured on HITConsultant, which provides healthcare technology news, analysis and insights for healthcare executives, physicians and providers. "US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating...
Interview with DocWireNew: Dr. Rollie Carlson, CEO, Immunexpress: Providing RAPID Detection for Sepsis
DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment. https://youtu.be/Vd0FL3fYPwY
Interview with Dr Rolland Carlson and Dr Richard Brandon
Download the Drug Target Review interview with Dr. Rolland Carlson and Dr. Richard Brandon.(pdf) The 2022 Drug Target Review Assays ebook, includes an interview about our sepsis detection initiative. In this collection of articles, Dr. Rolland Carlson and Dr. Richard Brandon, Immunexpress, answer questions about molecular...
Immunexpress Announces the Launch of New SeptiCyte RAPID® CE-IVD EDTA Blood Compatible Cartridges
SEATTLE, Aug. 23, 2022 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the launch of new SeptiCyte RAPID® EDTA blood compatible cartridges for the European market. The updated SeptiCyte® RAPID CE-IVD cartridge adds undiluted EDTA blood as a validated sample type, representing...
A Paradigm Shift in Sepsis Diagnostics
By Anna MacDonald of Technology Networks Immunexpress is advancing next-generation clinical sepsis diagnosis tests for use in emergency room and intensive care unit settings. The company’s lead test SeptiCyte® RAPID is clinically validated and has received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. It is the...
Tips For Obtaining Your 510(k) FDA Clearance
By Rolland Carlson, Ph.D., CEO, Immunexpress Our SeptiCyte RAPID clinical test received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. Sepsis is a life-threatening medical condition. Every minute counts for these patients in the ER and ICU. Clinicians in these settings need processes to distinguish sepsis patients...
Data Supporting SeptiCyte® RAPID Performance for COVID-19 Patient Triage Presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) by Immunexpress Collaborator
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced data presented by Immunexpress collaborator from a study supporting SeptiCyte® RAPID performance for COVID-19 patient triage at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) hybrid event, taking place online and...
A commercial rapid host-response test in COVID-19 severity stratification and triage
In a late-breaker presentation onsite, Immunexpress collaborators at Hospital Foch, France evaluated the performance of SeptiCyte® RAPID using patient samples from COVID-19 positive cases, in a study supported by Immunexpress partner Biocartis and the Biomedical Advanced Research and Development Authority (BARDA).
Immunexpress CEO To Present at the Virtual Biotech Showcase 2022
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today that Chief Executive Officer, Rolland Carlson, Ph.D., to present a corporate update, accessible on-demand, at the virtual Biotech Showcase 2022 to be held Jan. 10-12 and Jan. 17–19, 2022. Dr. Carlson will present...
If you are a member of the media, please contact:
Scott Stachowiak
Russo Partners
(646) 942-5630
scott.stachowiak@russopartnersllc.com